Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief Summary: This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.


Options:
A: Arm Label: Placebo (for Dupilumab 200 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Placebo (for Dupilumab 300 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Inhaled corticosteroid (ICS) therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Albuterol/Salbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Levalbuterol/Levosalbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w
B: Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Placebo q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Dupilumab 200 mg q4w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: ICS/LABA therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Levosalbutamol/levalbuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Intervention Type: DRUG; Name: Anti-IgE antibody omalizumab or placebo; Assigned to Arm(s): 1, 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D